CD34 and acute myeloid leukemia: Subsequently, we treated various primary AML samples, cord blood (CB) CD34+ cells, and CD34+ peripheral blood stem cells (PBSC) with an increasing dose of FT671 ranging from 4 nM to 2.5 μM for a period of 8 days on stroma.